UPDATE 2-Eliquis, Orencia sales propel Bristol-Myers to strong second quarter
July 25, 2019 at 13:22 PM EDT
Bristol-Myers Squibb Co , which is set to buy biotechnology company Celgene Corp for $74 billion, posted better-than-expected second-quarter profit on Thursday on strong sales of blood thinner Eliquis and rheumatoid arthritis treatment Orencia.